Absci is trading at $9.16, with a -10.76% change in the October 7, 2026 session; no verified company-specific announcement explains the decline.
- Recent coverage discusses Absci’s Phase 2 trial plans but does not establish them as the cause. XBI was down 2.50% in the provided session context.
- Broader risk-off pressure included rising oil prices and Treasury yields, alongside investor caution around Federal Reserve policy. Trading volume information was not provided.